Human platelets frozen with glycerol in liquid nitrogen: biological and clinical aspects

Hervé, Pierre‐Louis; Potron, G; Droule, C.; Beduchaud, M.P.; Masse, M; Coffe, C; Bosset, J.F.; Peters, A

doi:10.1046/j.1537-2995.1981.21481275993.x

Cited by 16 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notwithstanding the hopes and great scientific effort so far, the technology of platelet freezing has produced disappointing results. The majority of protocols require deep freeze storage capability and involve the use of dimethyl sulfoxide as a cryoprotectant (56–58), although glycerol, glucose and other reagents have also been used (59–61). In more recent years, a novel approach to platelet freezing has been developed by including a number of chemicals able to reduce platelet activation and the significant damages produced in vital components of the platelet structure by the thermal transitions occuring during freezing and thawing in the solutions used in the cryopreservation process (62).…”

Section: Preparation and Quality Control Of Platelet Concentratesmentioning

confidence: 99%

REVISITATIONOFTHE CLINICAL INDICATIONSFORTHE TRANSFUSIONOF PLATELET CONCENTRATES

Rebulla¹

2001

Rev Clin Exp Hematol

View full text Add to dashboard Cite

Platelet transfusion is indicated when the expected benefits of increasing the number of functional platelets in the patient's circulation outweigh the potential risks generated by exposing the patient to allogeneic, manipulated and stored blood products such as platelet concentrates. Although reassuring evidence has been collected indicating that current risks associated with blood transfusion are lower than those of several voluntary and involuntary human activities, balancing benefits and risks of platelet transfusion may not be easy in a proportion of patients and in a number of conditions. To facilitate this task, guidelines have been developed, with particular attention to cancer patients. As witnessed by the most recent guidelines, over the last few years there has been a progressive, although not absolute, consensus on: (i) the routine use of platelets as a tool to prevent hemorrhage in oncohematology (the so called 'prophylactic approach') as opposed to limiting platelet transfusion to actual bleeding episodes (the so-called 'therapeutic approach') and (ii) lowering the trigger for prophylactic platelet transfusion in stable oncohematology recipients from 20 x 109 to 10 x 109 platelets/L. This has been accompanied by a reduction of platelet use per oncohematology patient of about 20%, an important outcome in view of the progressive increase of platelet demand due to more aggressive therapy in cancer patients. In selected clinical conditions, specific triggers ranging from 30 x 10(9) to 100 x 10(9) platelets/L have been recommended, with higher values when surgical procedures are required for the patient's treatment. Indications and trigger values proposed in the guidelines must be considered within the context of careful clinical evaluation of each patient, with a clear appreciation of the power of discrimination of automated platelet counters at low counts, and of the quality and local availability of platelet products for emergency.

show abstract

Section: Preparation and Quality Control Of Platelet Concentratesmentioning

confidence: 99%

REVISITATIONOFTHE CLINICAL INDICATIONSFORTHE TRANSFUSIONOF PLATELET CONCENTRATES

Rebulla¹

2001

Rev Clin Exp Hematol

View full text Add to dashboard Cite

show abstract

“…Several modifi cations have been attempted to improve or simplify the technique with satisfactory in vitro results and clinical trials [6][7][8][9][10][11]. However, some investigators have obtained poor results and judged the glycerol methods to be gen erally inferior to techniques using DMSO as the cryoprotectant [12][13][14][15][16][17], We report here a standardized technique which incor porates important recent modifications of the glycerolglucose method to overcome some of the problems encountered earlier [3,5], Acidified plasma had been used together with other measures to reduce the frequency of post-thaw clumping, but the survival of such frozen plate let concentrates (PC) was often less than optimal.…”

Section: Introductionmentioning

confidence: 99%

Improved Procedure for Platelet Freezing

Dayian¹,

Harris²,

Vlahides³

et al. 1986

Vox Sanguinis

View full text Add to dashboard Cite

Platelets frozen in glycerol-glucose frequently aggregated on thawing or reconstitution. This has been eliminated by using a nonplasma diluent (pH 6.5) and a new freezing bag. The results were improved platelet 14C-serotonin uptake and readily demonstrable aggregation to ADP, epinephrine, collagen and thrombin. 14C-serotonin uptake was at maximum when platelets were frozen at thrombocrits of up to 15%. Hemostatic effectiveness was demonstrated in a severely thrombocytopenic patient with acute myelogenous leukemia in relapse, who was supported entirely with two autologous frozen platelet transfusions for the 13 days before bone marrow activity resumed.

show abstract

Platelets and Propylene Glycol: An Approach to Freezing Platelets in the Presence of a New Cyroprotectant

Arnaud¹,

Hunt²,

Pegg³

1987

White Cells and Platelets in Blood Transfusion

View full text Add to dashboard Cite

Human platelets frozen with glycerol in liquid nitrogen: biological and clinical aspects

Cited by 16 publications

References 20 publications

REVISITATIONOFTHE CLINICAL INDICATIONSFORTHE TRANSFUSIONOF PLATELET CONCENTRATES

REVISITATIONOFTHE CLINICAL INDICATIONSFORTHE TRANSFUSIONOF PLATELET CONCENTRATES

Improved Procedure for Platelet Freezing

Platelets and Propylene Glycol: An Approach to Freezing Platelets in the Presence of a New Cyroprotectant

Contact Info

Product

Resources

About